爱德华兹生命科学公司(EW)今日盘后股价大涨7.18%,引发市场广泛关注。消息面上,爱德华兹公司2024年第四季度业绩表现亮眼,成为推动股价上涨的主要原因。
财报数据显示,第四季度该公司每股收益为0.59美元,超出市场预期的0.55美元;销售额达到13.9亿美元,也高于预期的13.58亿美元。盈利和营收的双超预期,体现出爱德华兹业务发展势头良好。
业绩增长主要得益于该公司核心产品人工心脏瓣膜等医疗设备的销售持续旺盛。随着人口老龄化、疾病发生率上升,医疗手术需求不断增加,推动了公司医疗设备需求持续上行。此外,爱德华兹近期并购了多家心脏设备供应商,也有助于扩大在细分领域的市场份额,助力业务良性发展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.